Kim Kardashian has found herself in trouble with the FDA over one of her Instagram posts.
The 34-year-old recently bigged up morning sickness tablets Diclegis on her social media account, with the post getting over 466,000 likes. It later emerged that she was paid for it.
But now, the Food and Drug Administration have released a statement slamming Kim and deeming her promotion dangerous.
'The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information', it reads.
The pregnant star has now taken down her post, and the drug company that create Diclegis have responded with a statement of their own.
'Duchesnay USA takes its regulatory responsibilities very seriously, and acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations,' the company said.
Read more at http://www.look.co.uk/fashion/kim-kardashians-baby-bump-just-mysteriously-disappeared?utm_campaign=kimfda&utm_source=facebook&utm_medium=social#wjiRqJi1QlhJev8b.99
has found herself in trouble with the FDA over one of her Instagram posts.
The 34-year-old recently bigged up morning sickness tablets Diclegis on her social media account, with the post getting over 466,000 likes. It later emerged that she was paid for it.
But now, the Food and Drug Administration have released a statement slamming Kim and deeming her promotion dangerous.
'The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information', it reads.
The pregnant star has now taken down her post, and the drug company that create Diclegis have responded with a statement of their own.
'Duchesnay USA takes its regulatory responsibilities very seriously, and acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations,' the company said.
Read more at http://www.look.co.uk/fashion/kim-kardashians-baby-bump-just-mysteriously-disappeared?utm_campaign=kimfda&utm_source=facebook&utm_medium=social#wjiRqJi1QlhJev8b.99
has found herself in trouble with the FDA over one of her Instagram posts.
The 34-year-old recently bigged up morning sickness tablets Diclegis on her social media account, with the post getting over 466,000 likes. It later emerged that she was paid for it.
But now, the Food and Drug Administration have released a statement slamming Kim and deeming her promotion dangerous.
'The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information', it reads.
The pregnant star has now taken down her post, and the drug company that create Diclegis have responded with a statement of their own.
'Duchesnay USA takes its regulatory responsibilities very seriously, and acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations,' the company said.
Read more at http://www.look.co.uk/fashion/kim-kardashians-baby-bump-just-mysteriously-disappeared?utm_campaign=kimfda&utm_source=facebook&utm_medium=social#wjiRqJi1QlhJev8b.99
Kim Kardashian has shilled for a wide variety of different products, including diet pills and Silly Bandz, but her recent promotion of a morning sickness drug on social media has gotten her into some hot water with the FDA.
An Instagram picture featuring Kardashian, morning sickness drug Diclegis and an accompanying text promoting the drug's benefits, gained more than 450,000 "likes" but brought about a formal FDA warning letter for the drug's manufacturer.
"The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information", a part of the letter reads.
Kim has since taken down the post and the drug company has also released a statement of their own.
"Duchesnay USA takes its regulatory responsibilities very seriously, and acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations," the company said.
The FDA warning letter also requests Duchesnay offer corrections to the claims "using the same media" for the same audience.
0 comments:
Post a Comment